Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $392K | $150K | $230K | $650K | $659K | $294K | $574K | $0.00 | — | — |
| Revenue growth | — | -61.8% | 53.5% | 183.2% | 1.4% | -55.4% | 95.2% | -100.0% | — | — |
| Operating income | -$6.10M | -$4.83M | -$6.00M | -$5.93M | -$7.89M | -$10.4M | -$11.9M | -$12.6M | -$9.34M | -$7.29M |
| Operating margin | -1555.4% | -3228.8% | -2612.5% | -912.0% | -1197.3% | -3542.5% | -2072.0% | — | — | — |
| Net income | -$7.28M | -$5.68M | -$6.19M | -$6.37M | -$7.89M | -$10.4M | -$12.0M | -$12.2M | -$13.4M | -$7.15M |
| Net margin | -1855.8% | -3795.9% | -2697.8% | -980.3% | -1196.6% | -3540.9% | -2094.9% | — | — | — |
| EPS (diluted) | -$0.94 | -$0.10 | -$5.13 | -$1.87 | -$0.65 | -$0.71 | -$5.86 | -$38.87 | -$85.77 | -$10.61 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.51M | -$3.91M | -$4.29M | -$5.20M | -$6.76M | -$9.77M | -$10.5M | -$10.1M | -$7.65M | -$7.00M |
| Capital expenditures | $16.4K | $24.8K | $0.00 | $152K | $59.9K | $349K | $943K | $251K | $0.00 | $3.70K |
| Free cash flow | -$3.52M | -$3.94M | -$4.29M | -$5.35M | -$6.82M | -$10.1M | -$11.4M | -$10.4M | -$7.65M | -$7.00M |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | — | — | $9.60M | $9.86M | $17.1M | $14.5M | $5.44M | $5.50M | $5.03M |
| Total assets | $1.73M | $7.35M | $4.12M | $10.4M | $10.7M | $19.4M | $17.5M | $8.25M | $7.36M | $6.33M |
| Total liabilities | $1.13M | $1.32M | $1.82M | $1.11M | $1.38M | $2.43M | $2.44M | $2.48M | $2.24M | $1.45M |
| Shareholders' equity | $676K | $6.13M | $2.43M | $9.41M | $9.43M | $17.0M | $15.1M | $5.77M | $5.12M | $4.89M |
| Retained earnings | -$93.8M | -$99.5M | -$106M | -$112M | -$120M | -$130M | -$142M | -$155M | -$168M | -$175M |
| Shares (wtd avg diluted) | 8.80M | 17.7M | 1.27M | 9.37M | 12.2M | 14.8M | 2.05M | 314K | 156K | 674K |
Every figure is extracted from AETHLON MEDICAL INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.